Berry announced that it has initiated a formal process to evaluate strategic alternatives for its Health, Hygiene and Specialties segment, or HH&S. HH&S is a provider of nonwovens, specialty films, and tapes for a broad range of end markets, including healthcare, hygiene, consumer, building and construction, and industrials. The company is considering a wide range of available alternatives to maximize shareholder value, including, but not limited to, a sale, strategic partnership or joint venture, spin-off to shareholders, or other separation transaction for some or all of the businesses within HH&S. Importantly, the company expects current members of the HH&S leadership team will continue to lead the business in any anticipated outcome.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BERY:
- Berry Global names Kevin Kwilinski CEO, Stephen Sterrett chairman
- Berry Global price target raised to $80 from $79 at Citi
- Berry Global weighing options for nonwovens unit, Bloomberg reports
- Berry Global price target raised to $78 from $73 at RBC Capital
- Berry Global sees FY23 EPS $7.30 , consensus $7.38